MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Entegrion Awarded up to $43.7 Million from Department of Defense for a Blood Product Technology

Entegrion Awarded up to $43.7 Million from Department of Defense for a Blood Product Technology

By

The RTP life sciences development company will apply the funding to the clinical development of Resusix®, its proprietary dehydrated pathogen-inactivated human plasma that holds promise as a substitute for fresh frozen plasma (FFP) in certain applications.
ShareThis Email PDF Print

Entegrion logo
We view this as a strong vote of confidence from the world’s leading defense organization. This contract award positions the company as a strategic player in the mainstream of blood plasma research and development.
Research Triangle Park, NC (PRWEB) October 04, 2011

Entegrion announced today it has received a contract valued up to $43.7 million from the Department of Defense. The RTP life sciences development company will apply the funding to the clinical development of Resusix®, its proprietary dehydrated pathogen-inactivated human plasma that holds promise as a substitute for fresh frozen plasma (FFP) in certain applications.

The Department of Defense (DoD) is funding the development of Resusix® through Phase 3 clinical trials and Biological License Application. The contract is structured as a base effort of $24 million for a two-year period of performance, with an option of $19.7 million for an additional two years.
Joseph DaCorta, Entegrion’s Chief Technology Officer, said, “We are extremely honored by the DoD’s ongoing support of the Resusix® program. Our focus is to offer a safer and more effective alternative for frozen blood plasma, which often is not readily available in austere and remote locations. In addition, Resusix® has tremendous potential for serving unmet medical needs in global health settings.”

John B. Mowell, the company’s Executive Chairman, said, “Entegrion and its management view this award as a significant milestone in the development of the company’s product portfolio. It clearly demonstrates Entegrion’s unique capabilities and extraordinary talent in developing and delivering complex product solutions to highly demanding DoD specifications. More so, we view this as a strong vote of confidence from the world’s leading defense organization. This contract award positions the company as a strategic player in the mainstream of blood plasma research and development. Entegrion is proud to be a part of North Carolina’s prominent and growing biotech family.”

The product will be Entegrion’s first Investigational New Drug (IND) filing. The company expects 10-15 clinical investigation sites to participate in each phase of the product’s clinical development and will start actively recruiting sites in the next month.

About Entegrion
Entegrion is a life sciences development company that is focused on improving the safety and availability of the world’s blood supply. Based in North Carolina’s Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality. Many of Entegrion’s advances in biologics are based on close collaborations with leading medical research institutions. Visit http://www.entegrion.com for more information.

In case you missed it

RSS From Medical Design & Outsourcing

  • Machine Bio wins first BioTools Innovator competition
    The new BioTools Innovator accelerator program awarded its first $200,000 grand prize to Machine Bio after a live vote last week. Claremont, California-based startup Machine Bio was founded by David Marash, who serves as CEO.  “Machine Bio’s mission is to develop and commercialize a transformative protein expression platform that drastically minimizes the process of making… […]
  • Hologic CEO Steve MacMillan salutes CFO Karleen Oberton, offers his outlook and talks M&A
    After interviewing Hologic CFO Karleen Oberton for Medical Design & Outsourcing‘s annual Women in Medtech issue, we connected with CEO Steve MacMillan to get his take. He offered praise for his finance chief’s leadership throughout the pandemic, shared his outlook for the Marlborough, Massachusetts–based company’s future and discussed the M&A strategy for Hologic (NSDQ:HOLX), which… […]
  • Forecasting the future of urology with Boston Scientific’s Meghan Scanlon
    Meghan Scanlon, Boston Scientific’s president of urology and pelvic health, discusses the field and the challenges and opportunities ahead. The urology specialty faces a critical moment, with 10 urologists ready to retire for every new urologist entering the field, said Meghan Scanlon, SVP and president of urology and pelvic health at Boston Scientific (NYSE:BSX) That… […]
  • Women researchers receive a fraction of funding from the world’s biggest medtech companies
    The gender divide in medtech extends beyond leadership and into funding for investigational studies by U.S. physicians. Only 6.7% of physicians who received research payments from the world’s largest medical device companies in 2020 were women, according to an analysis of Medical Design & Outsourcing’s Big 100 list of medtech companies and CMS Open Payments… […]
  • Pentax Medical expands Vizient contract to include pediatric endoscopes
    Pentax Medical today announced it has expanded its contract with Vizient to include pediatric endoscopes. The contract will give Pentax Medical the ability to offer endoscopes to Vizient member hospitals through the Vizient Pediatric Program. The agreement also includes other value-added offerings, education opportunities and best practices. Get the full story on our sister site,… […]
  • Hologic plans to buy Bolder Surgical for $160M
    Hologic Inc. (NSDQ:HOLX) has a $160 million deal to acquire Bolder Surgical, a developer and manufacturer of advanced energy vessel sealing surgical devices. It’s the latest deal by Hologic, which has been spending COVID-19 test revenue generated by its diagnostics business on acquisitions across the company’s business lines, as CFO Karleen Oberton and CEO Steve MacMillan… […]
  • Koya Medical reports positive early results in Dayspring lymphedema trial
    Koya Medical this week announced positive results from a small, ongoing trial comparing its Dayspring compression treatment for lymphedema to a traditional pneumatic compression pump. The Oakland, California-based company secured FDA 510(k) clearance for the device last month, saying it was the first such approval for an active compression treatment enabling movement and mobility with… […]
  • OneProjects raises $17M to advance 4D cardiac imaging
    Irish-German cardiac imaging startup OneProjects today announced $8 million in Series A2 funding and two grants totaling $9 million. The company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, Verafeye. The… […]
  • Women in Medtech 2021: Lindsay Fleming, Avient Corp. Commercial Manager, Healthcare — Color & Additives
    Lindsay Fleming is the Healthcare Commercial Manager for the Color & Additives division at Avient Corporation, a premier provider of specialty polymer formulations, color and additive systems, packaging solutions, and polymer distribution. She has been with the company for over 7 years and oversees the commercial growth development of the healthcare segment. She focuses on… […]
  • Women in Medtech 2021: Sarah Ehrlich, Argon Medical Devices Sustaining Mechanical Engineer
    Sarah Ehrlich, sustaining mechanical engineer at Argon Medical Devices, holds a B.S in mechanical engineering from the University of Texas at Tyler. “My parents knew I would become an engineer before I did,” she said. “Growing up, I was the big sister who put back together whatever my younger siblings decided to tear apart. I… […]
  • Four questions with AdvaMed’s Jen Brearey
    Jen Brearey is AdvaMed’s chief financial officer and chief operating officer, as well as executive director for the association’s inclusion diversity programs, which includes the industry initiative AdvaMed Advance and AdvaMed’s Women’s Executive Network. Ahead of our annual Women in Medtech edition of Medical Design & Outsourcing, we asked Brearey to share her expertise on gender… […]

Leave a Reply